Loomis Sayles & Co. L P Lowers Holdings in Illumina, Inc. (NASDAQ:ILMN)

Loomis Sayles & Co. L P trimmed its holdings in Illumina, Inc. (NASDAQ:ILMN) by 3.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,210,160 shares of the life sciences company’s stock after selling 132,580 shares during the quarter. Illumina makes up approximately 60.8% of Loomis Sayles & Co. L P’s holdings, making the stock its 28th biggest position. Loomis Sayles & Co. L P owned 2.65% of Illumina worth $562,604,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds have also recently modified their holdings of ILMN. WCM Investment Management LLC increased its holdings in Illumina by 26.6% in the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company’s stock valued at $551,625,000 after acquiring an additional 867,673 shares during the last quarter. ARK Investment Management LLC bought a new stake in shares of Illumina in the fourth quarter worth about $91,714,000. Janus Henderson Group PLC lifted its position in shares of Illumina by 40.5% in the third quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company’s stock worth $282,735,000 after buying an additional 625,245 shares in the last quarter. Nikko Asset Management Americas Inc. bought a new position in Illumina during the fourth quarter valued at approximately $65,813,000. Finally, Sumitomo Mitsui Trust Group Inc. grew its holdings in Illumina by 116.9% during the 4th quarter. Sumitomo Mitsui Trust Group Inc. now owns 865,546 shares of the life sciences company’s stock valued at $115,663,000 after buying an additional 466,519 shares in the last quarter. Institutional investors own 89.42% of the company’s stock.

Wall Street Analyst Weigh In

ILMN has been the subject of a number of research reports. TD Cowen downgraded Illumina from a “buy” rating to a “hold” rating and lowered their target price for the company from $177.00 to $140.00 in a research report on Friday, February 7th. Robert W. Baird decreased their price target on shares of Illumina from $127.00 to $90.00 and set a “neutral” rating on the stock in a research note on Wednesday, March 5th. Hsbc Global Res cut shares of Illumina from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 28th. Barclays restated an “underweight” rating on shares of Illumina in a research report on Tuesday, March 11th. Finally, Canaccord Genuity Group lowered their price target on shares of Illumina from $135.00 to $115.00 and set a “hold” rating for the company in a report on Tuesday, March 11th. One analyst has rated the stock with a sell rating, ten have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat.com, Illumina has a consensus rating of “Moderate Buy” and a consensus target price of $140.90.

Illumina Trading Down 5.4 %

ILMN stock opened at $82.83 on Thursday. The company has a market capitalization of $13.12 billion, a PE ratio of -10.79, a P/E/G ratio of 1.60 and a beta of 1.17. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.77 and a quick ratio of 1.42. Illumina, Inc. has a 12 month low of $80.18 and a 12 month high of $156.66. The firm’s 50-day moving average is $105.03 and its 200 day moving average is $127.40.

Illumina (NASDAQ:ILMN) last issued its earnings results on Thursday, February 6th. The life sciences company reported $0.86 EPS for the quarter, missing analysts’ consensus estimates of $0.92 by ($0.06). Illumina had a positive return on equity of 13.37% and a negative net margin of 27.95%. On average, research analysts anticipate that Illumina, Inc. will post 4.51 EPS for the current year.

About Illumina

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.